Sonorant Therapeutics

Sonorant Therapeutics appears to refer primarily to a corporate naming vehicle associated with Mallinckrodt rather than an independent emerging biotech with a disclosed R&D pipeline. In 2019, Mallinckrodt announced plans for its remaining Specialty Brands company to be renamed Sonorant Therapeutics plc and to trade under the proposed ticker SRTX as part of a separation transaction, while a separate Irish legal entity, Sonorant Therapeutics Limited, was also formed in Dublin. Publicly available recent information indicates that Mallinckrodt continued operating under the Mallinckrodt name, and current disclosures do not show Sonorant as an operating standalone biotech company with a visible clinical pipeline, target portfolio, or platform technology. Accordingly, Sonorant is best characterized as a healthcare/pharma corporate entity or planned naming structure linked to Mallinckrodt's specialty and generics businesses rather than a conventional venture-backed therapeutics developer.